

## **A brief review on Viral Variants of Covid 19 infection**

### **Abstract**

SARS is a type of acute respiratory syndrome. Coronavirus 2 (SARSCoV2), a extremely contagious affecting the people worldwide. It lead to Coronavirus Disease 19 (COVID19), a rapidly spreading respiratory distress syndrome. In most countries it has caused a global pandemic and severe health crisis. Due to its continual evolution, further research into the virus's pathogenicity and virulence mechanisms, as well as the development of efficient therapy techniques, is urgently required. The current paper summarises what is known about the virus's evolutionary and structural features in order to better comprehend its mutational pattern and probable role in the current pandemic. In December 2019, the Coronavirus Disease (SARSCoV2) began a catastrophic path toward a global pandemic in Wuhan, China. Since then, several SARS CoV2 variants have been discovered. Despite the speedy development of a COVID19 vaccine and ongoing mass vaccination efforts around the globe, the discovery of latest SARSCoV2 variants could undermine the substantial success till now in stopping the spread of SARSCoV2. The goal of this review is to characterise the different SARS CoV2 mutations and investigate the associated morbidity and death.

Due to the virus's steady improvement, with its various unmarried nucleotide polymorphism (SNP) versions and lineages, figuring out SARS-CoV-2 infectivity is extraordinarily hard. but, similarly research into the virus's pathogenicity and virulence mechanisms, as well as the improvement of green therapy strategies, is urgently required. The present day contribution summarises existing expertise approximately the virus's evolutionary and structural homes with a view to clarify its mutational sample and ability function inside the ongoing pandemic.

### **Keywords :**

Variants , SARSCov2 , Pandemic , Viral variants , mutations , Coronavirus , Genetic diversity , strains , VOC , PCR , Variants of interest , Virulence , Vaccine , Duration of Vaccine.

### **Introduction**

In December two thousand nineteen, a novel form of coronavirus (CoV) was discovered in Wuhan. The virus spread fast over the world through human-to-human contact, quickly becoming a pandemic [1, 2]. Primary (fever, cough, dyspnea) and secondary (loss of smell, taste disorders, headache, gastrointestinal symptoms, skin lesions) symptoms are distinguished [3,4,5,6]. Since

then, it has wreaked havoc on social and economic systems all across the world. There is currently no anti-COVID19 antiviral medication that is both clinically useful and globally recognised (Remdesivir has actually shown great results, but further discussion is needed). Researchers are still working on new medications and vaccines [7].

Researchers have been trying to figure out the virus's genetic diversity since the outbreak began, looking for things like changes in immunological targets (glycoproteins), variations in primer and probe binding sites (limit diagnostic test sensitivity), and genetic variety (which may impact infectivity & virulence). [8,9,10,11]

Different variants, comprising nucleotide deletions in ORF8, have been discovered in addition to the wild type. The 382 variant (deletion in ORF7b and ORF8), which removes their transcriptional regulatory sequence, is the most well-known (this omission will prevent ORF8 transcription). Early in the outbreak, this variation propagated successfully, although it was not recognised until March 2020. These various varieties have been discovered in places around the world, including Bangladesh (three hundred forty five nucleotides), Australia (one hundred thirty eight nucleotides), and Spain (sixty two nucleotides). A passenger returning to Taiwan from Wuhan, China, identified the same 380 version in February 2020 [13, 14].

During the last pandemic in 2002-2003, SARSCoV caused the spread of zoonotic diseases from civet cats to humans. The wild-type virus mutated soon after & a new strain emerged. It contained a 29-nucleotide deletion in ORF8, dubbed 29. Following that, a deletion of 82 nucleotides and 415 nucleotides in the same area were discovered. Pandemic's impact on these weaknesses is not clear. In vitro studies have revealed, however, that the replication efficiency of 29 is lower than the wild type, and that the clinical sickness produced by it is milder [15, 16].

ORF8 promotes immunological evasion by downregulating MHC-I molecules, according to a recent study. In vitro investigations have also revealed that while these deletions have little effect on replication capacity, they do impact the transcription of several critical and defence genes, such as the ORF6 and N genes; therefore, compared to the wild type, more fragile variants can be created [17,18,19].

Other sections of the genome will be affected by mutations, and new mutations may occur, in addition to ORF8. The virus's highly variable peak (S) protein has been linked to an enhanced incidence of person-to-person transmission via interacting with the host's ACE2 receptor, according

to studies. Protein S; this transmembrane protein with 1255 amino acids aids the virus's binding and entry into the host [12, 20].

Mutations in genes have also been reported (RdRp). SARSCoV2 nsp12 is aRdRp with nine hundred thirty two AA spanning from 4393 to 5324 AA in a polyprotein. The polymerase domains of the SARSCoV2 nsp12 protein are separated structurally (398-919aa) [20].

Our purpose in this review is to report and analyse the influence of several SARSCoV2 variants and wild-type to see if they pose a significant concern to people.

## **AIM**

To study the viral variants of Covid.

## **Objective**

To assess the viral variants of Covid.

## **DISCUSSION**

SARS CoV2 has adapted to its new human host, as have other RNA viruses, but genetic evolution is likely to occur over time when mutations occur, resulting in mutant variations with features that differ from their ancestral strains. Several SARSCoV2 variants have been identified during the pandemic, and their impact on global public health is significant, however WHO has only considered a few.

The first to be described in the UK was Alpha (B.1.1.7) and then Gamma (P.1) was reported in SA. The first report would be published in India in December 2020.

The effect of novel SARSCoV2 polymorphisms on COVID19 pathogenesis, Is an essential monoclonal antibody target in vaccination serum. The N501Y mutation in RBD is one of them. Except for the Delta version, which causes spike protein to bind to the ACE 2 receptor, increasing virus binding and subsequent entrance into the host cell, other variants are common.

The alteration of the spike protein, in particular, can impair the antibody's affinity and binding to the SARSCoV2 cell's ACEII receptor. These VOC have a similar collection of mutations in common. Three major VOCs carry the N501Y mutation: B.1.1.7, P.1, and B.1.351. By enhancing affinity for ACEII, this mutation can increase the potential to spread. The E484K mutation diminishes neutralising antibody binding and leads to partial immune escape, which promotes reinfection and reduces the in vitro efficacy of some antibody or vaccination therapy.

These mutations can also have far-reaching phenotypic consequences. Furthermore, as demonstrated in some S gene tests, the accumulation of mutations creates a diagnostic risk (which is mitigated when many tests are employed). Many novel VOCs have been discovered as a result of

ongoing monitoring. The mutation E484K has been found in diverse parts of the world, which could indicate that SARSCoV2 has adapted to humans in the setting of increased immunity. Variations of Interest in SARS CoV2 (VOC). As new SARS CoV2 variations emerge, the CDC and WHO have developed their own classification system to separate developing new SARS CoV2 variants into varieties of interest (VOC) and varieties of interest (VOI).

### **Alpha** (lineage B.1.1.7)

PCR samples without the S gene were utilised to define variant B.1.1.7. There are 17 mutations in the viral genome of B.1.1.7. The spike protein N501Y has a higher affinity for ACE 2 receptor, resulting in better viral binding and subsequent host cell penetration.

This type of care has been in use in the United Kingdom from September 2020, and it is based on several model forecasts. Its infectivity has allegedly increased by 43 percent to 82 percent, exceeding the previous SARSCoV2 variety and becoming the utmost SARSCoV2 variant in the UK. In late Dec. two thousand twenty, B.1.1.7 was discovered in the USA. Persons infested with strains of the B.1.1.7 lineage, however, had a more severe sickness as compared to other routes of virus transmission, according to subsequent research studies. Persons infested with lineage variant B.1.1.7 had a risk ratio for mortality of 1.64 when compared to previously transmitted patient strains, according to a large matched cohort study done in UK. When compared to other SARSCoV2 mutations, Variant B 1.1.7 was found to be associated with greater mortality (HR = 1.61, 95 percent CI: 1.421.82). When compared to those with SARSCoV2 # 1.1.1.7, people with a validated B.1.1.7 mutation have a higher chance of mortality.

### **Beta** (lineage B.1.351)

Tegally and colleagues Multiple spike mutations have been discovered in a new version of the B.1.351 lineage of SARS CoV2, GH501Y.V2 is another name for the Beta variant, which will lead to the second wave of COVID19 infection in SA, in October 2020. The United States reported SARSCoV2 501Y.V2 in late January 2021. (lineage B.1.351). This variation has a greater risk of transmission, as well as a lower ability to neutralise monoclonal antibody treatment, convalescent serum, and serum following immunisation.

### **Gamma** (lineage P.1)

P.1 variation, another name- the Gamma variant or GR / 501Y.V3, was initially detected in the US in January 2021 and discovered in Brazil December 2020. The peak protein of variant B.1.1.28 has ten mutations (L18F, T20N, P26S, D138Y, R190S, H655Y, T1027I V1176, K417T, E484K and N501Y). RBD has three mutations (L18F, K417N, and E484K), which are identical to variation B.1.351. The mutation has spread to 45 countries, according to the World Health Organization's March 30, 2021 epidemiological bulletin. This polymorphism has the potential to reduce monoclonal antibody neutralisation, convalescent serum neutralisation, and postvaccination serum neutralisation.

#### **Delta (lineage B.1.617.2)**

The Delta variety, also known as B.1.617.2, was discovered in India in December 2020 and was responsible for the fourth fatality in April. In India, the second wave of COVID19 infection will occur in 2021. This strain was first discovered in the United States in March 2021, and it will quickly become the most prevalent SARSCoV2 strain in the country. The Delta variant was initially assumed to be a variant of interest. This mutation, however, quickly spread over the world, causing the WHO to classify it as a VOC in May 2021. There are ten mutations in variation B.1.617.2's peak protein (T19R, (G142D \*), 156del, 157del, R158G, L452R, T478K, D614G, P681R, and D950N).

In December two thousand nineteen, a novel form of coronavirus (CoV) was discovered in Wuhan. The virus spread fast over the world through human-to-human contact, quickly becoming a pandemic [1, 2]. Primary (fever, cough, dyspnea) and secondary (loss of smell, taste disorders, headache, gastrointestinal symptoms, skin lesions) symptoms are distinguished [3,4,5,6]. Since then, it has wreaked havoc on social and economic systems all across the world. There is currently no anti-COVID19 antiviral medication that is both clinically useful and globally recognised (Remdesivir has actually shown great results, but further discussion is needed). Researchers are still working on new medications and vaccines [7].

Different variants, comprising nucleotide deletions in ORF8, have been discovered in addition to the wild type. The 382 variant (deletion in ORF7b and ORF8), which removes their transcriptional regulatory sequence, is the most well-known (this omission will prevent ORF8 transcription). Early

in the outbreak, this variation propagated successfully, although it was not recognised until March 2020. These various varieties have been discovered in places around the world, including Bangladesh (three hundred forty five nucleotides), Australia (one hundred thirty eight nucleotides), and Spain (sixty two nucleotides). A passenger returning to Taiwan from Wuhan, China, identified the same 380 version in February 2020 [13, 14].

### **SARSCoV2 Variants of Interest (VOI)**

Variants with greater transmissibility or virulence, poorer neutralisation of antibodies produced by natural infection or vaccination, and the ability to elude detection or impede treatment or vaccine efficacy are all characteristics of mutations with unique genetic markers. Epsilon (B.1.427 and B.1.429); Zeta (P. 2); Eta (B.1.525); Theta (P.3); Iota (B.1.526); Kappa (B.1.617.1) and Lambda (B.1.617.1) are the seven variations of interest (VOI) described in the WHO weekly epidemiological report on June 22, 2021. (C.37).

Around June 2020, Epsilon (B.1.427 and B.1.429) variants, commonly known as CAL.20C/L452R, arose in the United States, increasing from 0% to > 50% of sequenced cases. Between September 2020 and January 29th, 2021. The transmissibility has increased by 18.624 percent in 2021 compared to the widespread wild-type strains. Specific mutations can be found in these versions (B.1.427: L452R, D614G; B.1.429: S13I, W152C, L452R, D614G). The CDC has designated this strain as a variation of concern in the United States due to its high transmissibility.

Zeta (P.2) has a key peak mutation and was first found in Brazil in April 2020, maybe as a result of the use of antibodies and vaccine serum therapy. Because it diminishes the neutralising effect, the WHO and CDC have classed this variation as a VOI.

The Eta (B.1.525) and Iota (B.1.526) variants, which contain crucial peak mutations (B.1.525: A67V, 69 / 70, 144, E484K, D614G, Q677H, F888L; B.1.526: (L95F) \*, D253G, (S477N \*), (E484K \*), D614G, (A701V \*), Eta (Antibodies and vaccination serum may be used less frequently in treatment.

In February 2021, theta variant (P.3), also known as GR/1092K.V1, was first found in the Philippines and Japan, and WHO categorised it as of interest. It carries a key peak mutation (deleted 141143 E484K; N501Y; and P681H).

The Kappa variation (B.1.617.1) was discovered in India in December 2021. It is classed as an interest by WHO and the Centers for Disease Control and Prevention. Because this variety is more widespread in South America, the Lambda variant (C.37) was discovered for the first time in Peru and was designated as a VOI by the WHO in June 2021.

VOC and VOI are Epsilon variations (B.1.427 and B.1.429) and Eta (B.1.525); Iota (B.1.526); Kappa (B.1.617.1); Zeta (page 2); B.1.526.1; B.1.617 and B.1.617.3 respectively, according to the CDC.[21,22,23,24,25]

### **Vaccine activity against variants**

A recurrent question from the time of development of viral variations has been whether newly produced vaccinations are effective?. According to vaccination statistics from Israel, Pfizer's BioNTech SE vaccine is 92% effective against all diseases, including infections caused by B.1.1.7, which is contained in B.1.1.7. Although B.1.1.7 did not completely elude immune protection, antibody neutralisation was reduced in 40 patients who received Pfizer's BioNTech vaccine. 33 To establish the efficiency of vaccinations against variations, larger research are required. The spike protein in the British variety differs from the spike protein in the Pfizer vaccination by only 9 amino acids. The Moderna vaccine has been demonstrated to be efficacious in vitro against the United Kingdom (B.1.1.7) and South Africa (B.351). In versions B.1.351, P.1, and B.1.1.7, it has been discovered to target the E484 mutation. The level of neutralizing antibodies was significantly reduced. Even after only one injection, both the Moderna and PfizerBioNTech vaccines elicited a robust antibody response in humans and allowed them to recover from past virus exposure . 32 Vaccines have the potential to enhance the extensive immune response already established in previously infected persons.[26-32]

According to research, Regeneron Pharmaceuticals Inc.'s antibody cocktail is proven to be efficacious against B.1.1.7 and B.1.351. It avoids immune evasion variations by targeting several epitopes of the virus. United States and South Africa, Ad26COV2.S (Johnson & Johnson vaccine) had efficacy of 72 percent and 57 percent, respectively, while giving protection of a modest nature. (66 percent) in Latin America. Previous infection with COVID19 does not ensure protection against variant B.1.351, according to a clinical investigation employing the Novavax vaccination in South Africa. In comparison to B.1.1.7, the AstraZeneca vaccination against B.1.351 was proven to be efficacious (22 percent) (74 percent). As a result, AstraZeneca vaccines are no longer distributed or managed in South Africa. [33-42]

**Conclusion:** Existing vaccinations are being updated by pharmaceutical companies in order to improve their efficacy. The production period is projected to be around 6 weeks. Multivalent

vaccinations can be given as booster doses and are effective against multiple lineages. To achieve a wider distribution, the vaccine dose can also be changed.

To vaccinate the vast majority of the population, some governments propose to extend the duration between the first and second doses to 12 weeks. The normal duration is 3 to 4 weeks, which has piqued some scientists' interest. The key premise behind using an adequate vaccination dosage schedule is that we want to fully kill the virus rather than domesticate it and make it immune to vaccines, which is what happens with seasonal influenza. However, this is not a fear shared by everyone. Many people believe that allowing the entire community to combat the virus is preferable to protecting half of the population while keeping the other half exposed.

## References

1. Esmaeil M, Farzane B, Mohammad AS, Tayebbeh N, Hamid H, SeyedAhmad S. Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19) a review of current evidence. *Eur Arch Oto-Rhino-Laryngol*.2020. <https://doi.org/10.1007/s00405-020-06120-6>.
2. Mehraeen E, Hayati B, Saeidi S, Heydari M, Seyed AS. Self-care instructions for people not requiring hospitalization for coronavirus disease 2019 (COVID-19). *Arch Clin Infect Dis*. 2020. <https://doi.org/10.5812/archcid.102978>.
3. De Vito A, Fiore V, Princic E, Geremia N, PanuNapodano CM, Muredda AA, et al. Predictors of infection, symptoms development, and mortality in people with SARS-CoV-2 living in retirement nursing homes. *PLoS ONE*. 2021;16(3):e0248009-e.
4. De Vito A, Fau GN, Fiore V, Fau FV, Princic E, Fau PE, Babudieri S, Fau BS, Madeddu G, Madeddu G. Clinical features, laboratory findings and pre- dictors of death in hospitalized patients with COVID-19 in Sardinia Italy. *Eur Rev Med Pharmacol Sci*. 2020;24(14):7861–8.
5. Vaira LA-OX, Deiana G, Fois AG, Pirina P, Madeddu G, De Vito A, et al. Objective evaluation of anosmia and ageusia in COVID-19 patients: single–center experience on 72 cases. *Head neack*. 2020;42:1252–8.
6. Zinellu A, Arru F, De Vito A, Sassu A, Valdes G, Scano V, et al. The De Ritis ratio as prognostic biomarker of in-hospital mortality in COVID-19 patients.*Eur J Clin Invest*. 2021;51(1):13427.

7. SeyedAlinaghi S, Ghadimi M, Hajiabdolbaghi M, Rasoolinejad M, Abbasian L, Nezhad MH, et al. Prevalence of COVID-19-like symptoms among people living with HIV, and using antiretroviral therapy for prevention and treatment. *Curr HIV Res.* 2020;18:373–80.
8. Jary A, Leducq V, Malet I, Marot S, Klement-Frutos E, Teyssou E, et al. Evolution of viral quasispecies during SARS-CoV-2 infection. *Clin Micro- biol Infect.* 2020;26(11):1560-e1.
9. Álvarez-Díaz DA, Franco-Muñoz C, Laiton-Donato K, Usme-Ciro JA, Franco-Sierra ND, Flórez-Sánchez AC, et al. Molecular analysis of several in-house rRT-PCR protocols for SARS-CoV-2 detection in the context of genetic variability of the virus in Colombia. *Infect Genet Evolut.* 2020;84:104390.
10. Lokman SM, Rasheduzzaman M, Salauddin A, Barua R, Tanzina AY, Rumi MH, et al. Exploring the genomic and proteomic variations of SARS- CoV-2 spike glycoprotein: a computational biology approach. *Infect Genet Evolut.* 2020;84:104389.
11. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. *Cell.* 2020;182:812–27.
12. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. *Nature.* 2020;579(7798):265–9.
13. Su YCF, Anderson DE, Young BE, Linster M, Zhu F, Jayakumar J, et al. Discovery and genomic characterization of a 382-nucleotide deletion in ORF7b and ORF8 during the early evolution of SARS-CoV-2. *MBio.* 2020. <https://doi.org/10.1128/mBio.01610-20>.
14. Gong Y-N, Tsao K-C, Hsiao M-J, Huang C-G, Huang P-N, Huang P-W, et al. SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in middle East. *Emerg Microb Infect.* 2020;9(1):1457–66.
15. Consortium CSME. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. *Science.* 2004;303(5664):1666–9.
16. Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol.* 2018;17(3):181–92.
17. Muth D, Corman VM, Roth H, Binger T, Dijkman R, Gottula LT, et al. Attenuation of replication by a 29 nucleotide deletion in SARS-coronavirus acquired during the early stages of human-to-human transmission. *Sci Rep.* 2018;8(1):1–1.
18. Zhang L, Yang J-R, Zhang Z, Lin Z. Genomic variations of SARS- CoV-2 suggest multiple outbreak sources of transmission. *medRxiv.* 2020;7:154.
19. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature.* 2020;583(7816):459–68.

20. Bhowmik D, Pal S, Lahiri A, Talukdar A, Paul S. Emergence of multiple variants of SARS-CoV-2 with signature structural changes. *bioRxiv*. 2020;91:157.
21. Giovanetti M, Benedetti F, Campisi G, Ciccozzi A, Fabris S, Ceccarelli G, Tambone V, Caruso A, Angeletti S, Zella D, Ciccozzi M. Evolution patterns of SARS-CoV-2: Snapshot on its genome variants. *Biochem Biophys Res Commun*. 2021 Jan 29;538:88-91.
22. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM, Freeman TM, de Silva TI, Sheffield COVID-19 Genomics Group. McDanal C, Perez LG, Tang H, Moon-Walker A, Whelan SP, LaBranche CC, Saphire EO, Montefiori DC. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell*. 2020 Aug 20;182(4):812-827.e19.
23. Oreshkova N, Molenaar RJ, Vreman S, Harders F, Oude Munnink BB, Hakze-van der Honing RW, Gerhards N, Tolsma P, Bouwstra R, Sikkema RS, Tacke MG, de Rooij MM, Weesendorp E, Engelsma MY, Bruschke CJ, Smit LA, Koopmans M, van der Poel WH, Stegeman A. SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020. *Euro Surveill*. 2020 Jun;25(23)
24. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y, Chen Z, Guo Y, Zhang J, Li Y, Song X, Chen Y, Xia L, Fu L, Hou L, Xu J, Yu C, Li J, Zhou Q, Chen W. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. *Science*. 2020 Aug 07;369(6504):650-655.
25. Liu H, Zhang Q, Wei P, Chen Z, Aviszus K, Yang J, Downing W, Peterson S, Jiang C, Liang B, Reynoso L, Downey GP, Frankel SK, Kappler J, Marrack P, Zhang G. The basis of a more contagious 501Y.V1 variant of SARS-COV-2. *bioRxiv*. 2021 Feb 02;
26. Callaway, E. Rare COVID reactions might hold key to variant-proof vaccines. *Nature* 2021;592:20–21
27. Belluz, J, Irfan, U. How the new Covid-19 could pose a threat to vaccination. 2021.
28. Soucheray, S. New COVID-19 variants found in New York, California: Center for infectious disease research And policy, 2021.
29. Gale, J. Why the mutated coronavirus variants are so worrisome. 2021.
30. Muik, A, Wallisch, A-K, Sanger, B, Swanson, KA, Muhl, J, Chen, W, Cai, H, Maurus, D, Sarkar, R, Tureci. Neutralization of SARS-CoV-2 lineage B. 1.1. 7 pseudovirus by BNT162b2 vaccine–elicited human sera.
31. Wu, K, Werner, AP, Koch, M, Choi, A, Narayanan, E, Stewart-Jones, GB, Colpitts, T, Bennett, H, Boyoglu-Barnum, S, Shi, W. Serum neutralising activity elicited by mRNA-1273 vaccine.
32. Griffin, R, Langreth, R. J&J vaccine provides strong shield against severe Covid , 2021.

33. Bollinger, R, Ray, S. New variants of coronavirus: what you should know. 2021.
34. Fontanet, A, Autran, B, Lina, B, Kieny, MP, Karim, SSA, Sridhar, D. SARS-CoV-2 variants and ending the COVID-19 pandemic.
35. Acharya, Sourya, Samarth Shukla, and Neema Acharya. "Gospels of a Pandemic- A Metaphysical Commentary on the Current COVID-19 Crisis." JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH 14, no. 6 (June 2020): OA01–2. <https://doi.org/10.7860/JCDR/2020/44627.13774>.
36. Arora, Devamsh, Muskan Sharma, Sourya Acharya, Samarth Shukla, and Neema Acharya. "India in 'Flattening the Curve' of COVID-19 Pandemic - Triumphs and Challenges Thereof." JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS 9, no. 43 (October 26, 2020): 3252–55. <https://doi.org/10.14260/jemds/2020/713>.
37. Bawiskar, Nipun, Amol Andhale, Vidyashree Hulkoti, Sourya Acharya, and Samarth Shukla. "Haematological Manifestations of Covid-19 and Emerging Immunohaematological Therapeutic Strategies." JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS 9, no. 46 (November 16, 2020): 3489–94. <https://doi.org/10.14260/jemds/2020/763>.
38. Burhani, Tasneem Sajjad, and Waqar M. Naqvi. "Telehealth - A Boon in the Time of COVID 19 Outbreak." JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS 9, no. 29 (July 20, 2020): 2081–84. <https://doi.org/10.14260/jemds/2020/454>.
39. Butola, Lata Kanyal, Ranjit Ambad, Prakash Kesharao Kute, Roshan Kumar Jha, and Amol Dattarao Shinde. "The Pandemic of 21st Century - COVID-19." JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS 9, no. 39 (September 28, 2020): 2913–18. <https://doi.org/10.14260/jemds/2020/637>.
40. Dasari, Venkatesh, and Kiran Dasari. "Nutraceuticals to Support Immunity: COVID-19 Pandemic- A Wake-up Call." JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH 14, no. 7 (July 2020): OE05–9. <https://doi.org/10.7860/JCDR/2020/44898.13843>.
41. Dhok, Archana, Lata Kanyal Butola, Ashish Anjankar, Amol Datta Rao Shinde, Prakash Kesharao Kute, and Roshan Kumar Jha. "Role of Vitamins and Minerals in Improving Immunity during Covid-19 Pandemic - A Review." JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS 9, no. 32 (August 10, 2020): 2296–2300. <https://doi.org/10.14260/jemds/2020/497>.
42. Gawai, Jaya Pranoykumar, Seema Singh, Vaishali Deoraoji Taksande, Tessy Sebastian, Pooja Kasturkar, and Ruchira Shrikant Ankar. "Critical Review on Impact of COVID 19 and Mental Health." JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS 9, no. 30 (July 27, 2020): 2158–63. <https://doi.org/10.14260/jemds/2020/470>.

UNDER PEER REVIEW